Find drug development pipeline and deal Updates information

Lead Product(s): SCB-313

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

The Phase I, open-label, dose escalation trial in China is designed to assess the safety, tolerability, pharmacokinetics and efficacy of intrapleural administered SCB-313 for the treatment of MPE.

Lead Product(s): ADG106

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: General Atlantic

Deal Size: $69.0 million Upfront Cash: Undisclosed

Deal Type: Series D Financing January 08, 2020

Details:

Proceeds will support advancement of lead immunotherapy clinical programs ADG106 and extend the frontiers of novel technology.

Lead Product(s): IN10018, Pembrolizumab

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 06, 2020

Details:

InxMed will be the study sponsor and MSD will provide pembrolizumab to InxMed to use in the clinical study. This is the first global clinical collaboration between the two companies.